{'fraction_non_alphanumeric': 0.043333333333333335, 'fraction_numerical': 0.013333333333333334, 'mean_word_length': 5.3936170212765955, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Predicting the future: initial treatment response in neovascular age-related macular degeneration correlates strongly with long-term visual acuity

Age-related macular degeneration (AMD) is a sight-threatening disease and responsible for 8.7% of blindness globally (1). Neovascular AMD (nAMD) is characterized by abnormal angiogenesis with these atypical vessels leaking, resulting in fluid accumulation, haemorrhage and fibrosis which can lead to rapid central vision loss (2). Although nAMD makes up 15% of total AMD cases (2), it is responsible for the majority of cases of severe visual loss (3).